Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its ...

The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

Speeding up drug discovery in the age of AI may come down to a concept that's comfortingly old-fashioned: Consulting a ...

Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial ...

AI: How does this technological revolution fit with the pharmaceutical regulators who oversee the pharmaceutical sector at ...

Silicon Valley and Wall Street are pouring billions into AI drug discovery in a high-stakes bet to “solve” disease.

AI and machine learning are revolutionizing drug discovery, development, and lifecycle management, addressing industry ...

SOUTH SAN FRANCISCO, Calif., January 12, 2026--insitro, the AI therapeutics company built on causal biology, today announced the acquisition of CombinAbleAI and the launch of insitro’s TherML™ ...

Explore the innovative generative AI method transforming drug discovery and material science at unprecedented speeds.

The startup has partnered with Eli Lilly and enjoys the backing of some of Silicon Valley's most influential VCs.

Proxima, a biotech startup using artificial intelligence to design drugs that control protein interactions, raised $80 million in seed funding, which will help it collect better data and eventually ...

In this week’s edition of The Prototype, we look at using AI to find new drugs, quantum biotechnology, the ROI of generative ...